MedTrace Logo

PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton

NCT02496910 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2015-09-25

No results posted yet for this study

Summary

This is a Randomized, open-label, single-dose, 2-treatment, 2-period, 2-sequence crossover design.

Conditions

Interventions

DRUG

YH22162

DRUG

Telmisartan/Amlodipine 80/5 mg (FDC)

DRUG

Chlorthalidone 25mg

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Mingul Kim, MD, Ph.D · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02496910 on ClinicalTrials.gov